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This well-conducted, multi-centre randomised controlled trial (RCT) makes an important 
contribution to the surgical management of gastric cancer. It addresses the contentious role of 
bursectomy. Only one inconclusive RCT has examined this practice previously(1). The present, much 
larger trial reported by Kurokawa and colleagues resolves the ongoing uncertainty. Bursectomy was 
associated with a longer operative time, increased blood loss and increased rates of postoperative 
pancreatic fistula formation, without survival advantage. Bursectomy should therefore no longer be 
performed routinely in gastrectomy for cancer. 
 
The present trial demonstrated several features key to producing internally valid results(2). 
Treatment group was allocated centrally after intra-operative tumour assessment to confirm 
eligibility. Analysis was conducted on an intention-to-treat basis, and survival analysis provided 
information on censoring of cases according to follow-up at each time point. Outcomes were 
reported as stated in the protocol, mitigating against reporting bias. 
 
However, some methodological issues have been identified. Neither patients nor outcome assessors 
were blinded to treatment allocation. This would have been straight forward and would have 
reduced ascertainment bias, which is especially relevant given the focus on safety outcomes in this 
study. Another issue is the sample size and power. The study was set to test superiority and 
powered to test a one-sided hypothesis with only 80% power.  This was justified on the basis that 
bursectomy may increase complications although evidence for this came from the trial itself. Whilst 
allowance was made for the interim analysis there is concern that the trial is not sufficiently 
powered to exclude a survival benefit. 
 
In addition, it is important to consider the external validity of this trial, to determine how it ought to 
shape the practice internationally. The inclusion criteria, focusing on patients with cT3/4 disease and 
performance status of 0 or 1, provide a broad match to patients undergoing surgery in the UK(3), 
  
although US data suggests patients undergoing surgery there have slightly earlier disease(4). Beyond 
this, usual clinical practice in the UK and US includes surgery on patients with a performance status 
of 2, BMI >  30, and insulin-dependent diabetes, who were excluded from this trial(5). Further, 
routine splenectomy for proximal tumours is not commonly practiced outside Asia. These 
differences between the trial and more typical Western practice may not fatally compromise the 
generalisability of this trial’s results, but we question whether it was necessary to specify such 
inclusion and exclusion criteria. Broader inclusion criteria would have maximised the overall utility of 
trial findings(6). 
 
To participate in the trial, surgeons needed a large volume of experience, with over 100 previous 
gastrectomies and 20 bursectomies. Surgeons watched videos of both interventions being evaluated 
in the trial, and photographs of the dissection were taken for every case. This level of quality 
assurance to minimise performance bias is unusual in surgical trials and should be commended. 
More information about how the photographs were assessed for surgical quality would have been 
useful. The level of expertise among the study surgeons should be achievable by surgeons in other 
countries where gastric cancer surgery has been centralised, but may not be possible where care has 
not undergone a process of sub-specialisation. 
 
The 5 year overall survival rates in this study were 77% for both intervention groups, which are much 
higher than survival rates in Western practice(3,4). This marked difference has been reported 
previously. The difference may have been exaggerated in this study due to exclusion of patients that 
would be treated in usual practice in the West. This fundamental difference may be a source of 
concern regarding the application of this trial’s findings for many clinicians. In addition, neoadjuvant 
chemotherapy is common practice in the West. This may influence disease recurrence patterns and 
outcomes of surgery involving bursectomy, and this study does not include these patients. However, 
  
we consider that the basic oncological considerations regarding bursectomy versus non-bursectomy 
are likely to apply regardless of these considerations. 
 
In the study’s favour, its large, multicentre nature enhances its external validity. The details of 
perioperative care were not specified in the study protocol and will have varied across the 57 
included sites. This will have replicated natural practice variations within a health care system, 
increasing the applicability of the study findings in other settings. 
 
In summary, this trial is well designed and conducted. While there are some biases and cautions 
regarding its external validity, we consider that these are unlikely to have significantly compromised 
the trial result, or its relevance internationally. This trial ought, therefore, to shape practice 
internationally, promoting a shift away from bursectomy during gastrectomy for cancer while 
retaining the current gold standard of radical D2 lymphadenectomy.  
 
Conflict of interest statement 
 
The authors declare no conflicts of interest. 
 
References 
 
1.  Hirao M, Kurokawa Y, Fujita J, Imamura H, Fujiwara Y, Kimura Y, et al. Long-term outcomes 
after prophylactic bursectomy in patients with resectable gastric cancer: final analysis of a 
multicenter randomized controlled trial. Surgery [Internet]. 2015;157(6):1099–105. Available 
from: http://dx.doi.org/10.1016/j.surg.2014.12.024 
2.  Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane 
Collaboration’s tool for assessing risk of bias in randomised trials. Br Med J [Internet]. 
  
2011;343:d5928. Available from: http://www.bmj.com/cgi/doi/10.1136/bmj.d5928 
3.  Healthcare Quality Improvement Partnership Ltd. National oesophago-gastric cancer audit 
2016. 2016.  
4.  Datta J, Lewis RS, Mamtani R, Stripp D, Kelz RR, Drebin JA, et al. Implications of inadequate 
lymph node staging in resectable gastric cancer: a contemporary analysis using the National 
Cancer Data Base. Cancer. 2014;120(18):2855–65.  
5.  Bartlett EK, Roses RE, Kelz RR, Drebin JA, Fraker DL, Karakousis GC. Morbidity and mortality 
after total gastrectomy for gastric malignancy using the American College of Surgeons 
National Surgical Quality Improvement Program database. Surgery [Internet]. 
2014;156(2):298–304. Available from: http://dx.doi.org/10.1016/j.surg.2014.03.022 
6.  Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: 
designing trials that are fit for purpose. Br Med J [Internet]. 2015;350:h2147. Available from: 
http://www.bmj.com/cgi/doi/10.1136/bmj.h2147 
 
 
